Immunotherapy for Lung Cancer

Küçük Resim Yok

Tarih

2023

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Turkiye Klinikleri

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death re-ceptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 anti-bodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics. © 2023 by Turkish Society of medical oncology.

Açıklama

Anahtar Kelimeler

Biomarker, immune checkpoint inhibitor, immunotherapy, mutation, non-small cell lung cancer

Kaynak

Journal of Oncological Science

WoS Q Değeri

Scopus Q Değeri

Q4

Cilt

9

Sayı

2

Künye